Hidroxizina Pentafarma (Hydroxyzine Hydrochloride)

Hidroxizina Pentafarma is prescribed for several clinical situations where its antihistamine and central nervous system effects are beneficial.

• Relief of itching associated with allergic dermatoses such as urticaria or eczema.
• Management of generalized anxiety or tension in adults.
• Short‑term sedation before or after minor surgical or diagnostic procedures.
• Adjunctive treatment of nausea or vomiting related to anxiety or medication side effects.
• Control of pruritus in chronic liver disease or renal failure.

• Hydroxyzine hydrochloride acts as a selective antagonist of peripheral histamine H1 receptors, thereby preventing histamine‑mediated allergic responses. The drug readily crosses the blood‑brain barrier, where central H1 blockade contributes to its sedative and anxiolytic effects. Additional anticholinergic activity adds to its calming properties, while inhibition of serotonin release may further modulate mood and nausea.

Adverse reactions to Hidroxizina Pentafarma are generally related to its antihistaminic and anticholinergic activity.

Common

• Drowsiness or sedation
• Dry mouth
• Blurred vision
• Constipation
• Headache
• Dizziness

Serious

• Severe allergic reaction (anaphylaxis)
• Cardiac arrhythmias or QT interval prolongation
• Seizures
• Hepatic dysfunction
• Acute angle‑closure glaucoma

When prescribing Hidroxizina Pentafarma, clinicians should consider several safety factors.

• Do not use in patients with known hypersensitivity to hydroxyzine or related compounds.
• Use caution in the elderly, who may be more susceptible to sedation and anticholinergic effects.
• Avoid operating machinery or driving until the individual’s response to the drug is known.
• Adjust dosing in patients with hepatic or renal impairment, as clearance may be reduced.
• Pregnancy and lactation safety have not been established; use only if the potential benefit justifies the risk.
• Concomitant use with alcohol or other central nervous system depressants may enhance sedation.
• Monitor patients with glaucoma, urinary retention, or prostatic hypertrophy for worsening symptoms.

Hydroxyzine can interact with several medication classes, requiring attention to avoid adverse outcomes.

Avoid

• Other central nervous system depressants (e.g., benzodiazepines, opioids, alcohol).
• Additional antihistamines or anticholinergic agents, which may increase anticholinergic burden.
• Monoamine oxidase inhibitors (MAOIs) due to the risk of heightened serotonergic effects.
• Drugs known to prolong the QT interval, increasing the risk of cardiac arrhythmias.
• Strong CYP3A4 inhibitors that could raise hydroxyzine plasma concentrations.

Use with caution

• CYP3A4 inducers (e.g., rifampin) that may reduce hydroxyzine effectiveness.
• Certain antidepressants (e.g., tricyclics) that share anticholinergic properties.
• Antihypertensive agents, as hydroxyzine may cause additive hypotensive effects.
• Diabetic medications, because sedation could mask hypoglycemia symptoms.
• Other medications metabolized by the liver, requiring monitoring for altered drug levels.